SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001479290-21-000165
Filing Date
2021-11-09
Accepted
2021-11-09 16:17:44
Documents
83
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rvnc-20210930.htm   iXBRL 10-Q 2217166
2 EX-10.1 rvncq321exhibit101.htm EX-10.1 51978
3 EX-31.1 rvncq321exhibit311.htm EX-31.1 8771
4 EX-31.2 rvncq321exhibit312.htm EX-31.2 8783
5 EX-32.1 rvncq321exhibit321.htm EX-32.1 6500
6 EX-32.2 rvncq321exhibit322.htm EX-32.2 6538
  Complete submission text file 0001479290-21-000165.txt   8774400

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20210930.xsd EX-101.SCH 51342
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20210930_cal.xml EX-101.CAL 84395
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20210930_def.xml EX-101.DEF 283474
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20210930_lab.xml EX-101.LAB 637725
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20210930_pre.xml EX-101.PRE 432921
12 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20210930_htm.xml XML 1485586
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36297 | Film No.: 211392458
SIC: 2834 Pharmaceutical Preparations